Transcatheter mitral valve implantation via transapical approach: an early experience

Abstract

TMVI using the CardiAQ™ device via a transapical approach is feasible and effective.

Three-Dimensional Echocardiography Compared With Computed Tomography to Determine Mitral Annulus Size Before Transcatheter Mitral Valve Implantation

“…[1][2][3][4][5] Similar to transcatheter aortic valve implantation, determination of anatomic eligibility and valve sizing is contingent on preprocedural imaging. 6,7 It is well established that the mitral annulus (MA) contour is nonplanar and saddleshaped with 2 peaks; a posterior peak formed by the insertion of the posterior mitral valve leaflet and an anterior peak which extends to the level of the aortic valve and annulus.…”

First-in-Human Case of Transfemoral CardiAQ Mitral Valve Implantation

“…Interestingly, these challenges have been addressed in different ways, for example, by introducing a D-shaped stent design, annular versus apical anchoring, or a large inflow sealing area. [1][2][3][4] Also the CardiAQ prosthesis has been optimized since its first implant, as described in this report. The second-generation CardiAQ valve is built on the company's proprietary method for anchoring the implant through leaflet engagement, chordal preservation, and annular attachment, while offering improved flow properties and a novel feature for the prevention of paravalvular leaks.…”

“…In all cases, the TMVI procedures were performed by transapical approach ( Figure I in the Data Supplement). 1 The transapical approach seems to be more straightforward than the transfemoral approach as it demands less procedural steps. Moreover, obtaining axial alignment with the delivery system is much easier in the transapical procedure when compared with the transfemoral procedure.…”

Transcatheter Structural Heart Interventions for the Treatment of Chronic Heart Failure

“…Despite this, many systems have been tested in preclinical trials, and first-in-man data are available from 4 trancatheter mitral valve systems: the CardiAQ valve 54 (CardiAQ Valve Technologies, Inc, Irvine, CA, transfemoral and transapical systems), the Tiara valve 55 (Neovasc, Inc, Richmond, British Columbia, Canada), the Fortis TVM 56 (Edwards Lifesciences, Irvine, CA), and the Tendyne valve 57 (Tendyne Inc, Minneapolis, MN; Figure 10). Although transcatheter mitral valve replacement is still in a early development stage, it is expected that this technology will become a major player in the treatment of MR in the coming years among those patients considered at high or prohibitive surgical risk.…”